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Neonatal Cerebral Sinovenous Thrombosis From
Symptom to Outcome
Florieke J. Berfelo, MD; Karina J. Kersbergen, BM; C.H.(Heleen) van Ommen, MD, PhD;
Paul Govaert, MD, PhD; H.L.M.(Irma) van Straaten, MD, PhD; Bwee-Tien Poll-The, MD, PhD;
Gerda van Wezel-Meijler, MD, PhD; R. Jeroen Vermeulen, MD, PhD; Floris Groenendaal, MD, PhD;
Linda S. de Vries, MD, PhD; Timo R. de Haan, MD, PhD
Background and Purpose—Cerebral sinovenous thrombosis is a rare disease with severe neurological sequelae. The
aim of this retrospective multicenter study was to investigate the clinical course, possible risk factors, and outcome
of a cohort of neonatal patients with sinovenous thrombosis and, second, to estimate the incidence in The
Netherlands.
Methods—From January 1999 to March 2009, a review of all neonatal patients with sinovenous thrombosis from 6 tertiary
neonatal intensive care units was performed. Population characteristics, clinical presentation, (prothrombotic) risk
factors, neuroimaging, interventions, and neurodevelopment were evaluated. An estimated incidence was calculated
based on the Netherlands Perinatal Registry.
Results—Fifty-two neonates were included (39 boys) with a median gestational age of 39 weeks (range, 30 to 42 weeks;
5 preterm). An assisted or complicated delivery occurred in 32 of 52. Presenting symptoms developed at a median
postnatal age of 1.5 days (range, 0 to 28 days) and consisted mainly of seizures (29 of 52). All sinovenous thrombosis
cases were confirmed with MRI/MR venography. Multisinus thrombosis was most common followed by superior
sagittal sinus thrombosis. FII G20210A mutation was present in 2 of 18 tested neonates (11%). Anticoagulation therapy
(in 22 of 52) did not result in hemorrhagic complications. At follow-up (median age, 19 months; range, 3 to 72 months),
moderate to severe neurological sequelae were present in 38%. The mortality was 10 of 52 (19%). A variable, although
high yearly incidence of 1.4 to 12 per 100 000 term newborns was found.
Conclusions—Neonatal sinovenous thrombosis is a multifactorial disease. The estimated incidence in The Netherlands
seems higher than reported elsewhere. (Stroke. 2010;41:1382-1388.)
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Neonatal cerebral sinovenous thrombosis (SVT) is in-creasingly diagnosed due to greater clinical awareness
and improved neuroimaging techniques. Described inci-
dences of pediatric sinovenous thrombosis range from 0.35 to
0.67 per 100 000 children per year with a higher incidence in
neonates (2.6 to 2.69 per 100 000 newborns a year). An
important data source is the Canadian Pediatric Stroke Reg-
istry.1–3 The reported incidence of neonatal SVT is probably
an underestimation; many patients may remain unidentified
due to nonspecific clinical presentation, high dependence
on clinician awareness, and use of appropriate neuroimag-
ing techniques.4 Morbidity and mortality can, however, be
significant and depend on extent and localization of
thrombosis and associated cerebral parenchymal le-
sions.1,4 – 6 Adverse neurological sequelae consist of gen-
eral developmental delay, sensorimotor deficits, visual
impairments, and epilepsy.2,5– 8
Most studies on pediatric SVT include children of all
ages1,3,5,8 –12 and only few, usually small case-series, focus
on neonates.13–16 Therefore, the aim of our study was to gain
more knowledge regarding clinical presentation, recognition
of high-risk profiles, use of optimal neuroimaging techniques,
interventions, and outcome in a large group of exclusively
neonatal patients with SVT.
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Methods
A retrospective, multicenter review was performed in neonates
admitted to 6 of the 10 Level III neonatal intensive care units
covering the most densely populated areas of The Netherlands
between January 1999 and March 2009. Pediatric hematology,
radiology, and neonatology databases of all participating centers
were searched for patients with neonatal SVT. Only MRI and MR
venography (MRV)-proven SVT was included. Because this was a
retrospective study, data on suspected SVT cases were unreliable or
incomplete. To estimate yearly incidence of neonatal SVT, the number
of term deliveries (home- and hospital-based) in the regions of the
neonatal intensive care units concerned was requested from the Neth-
Figure 1. A, Axial T2-weighted spin echo (T2SE)
image showing predominantly left-sided punctate
white matter lesions. B, Time-of-flight MRV image
showing absent flow in the straight sinus.
Table 1. Population Characteristics of 52 Neonates With SVT
Parameter No. (%) or Median (Range)
Gestational age, weeks 39.0 (30–42)
Birth weight, g 3030 (1403–4415)
Apgar score 5 minutes 8.0 (3–10)
Apgar score 10 minutes 9.0 (3–10)
Male 39 (75%)
Female 13 (25%)
Caucasian 49 (94%)
African 3 (6%)
Umbilical cord pH (n13) 7.13 (6.76–7.27; n4, pH7.0)
Interval birth to symptoms, days 1.5 (0–28)
Interval symptoms to diagnosis, days 4.0 (0–26)
No. (%)
Clinical symptoms
Generalized seizure 18 (34.6%)
Focal seizure 11 (21.2%)
Apnea 9 (17.3%)
Asymptomatic (chance finding) 7 (13.4%)
Agitated 3 (5.8%)
Sepsis-like 2 (3.8%)
Depressed consciousness 1 (2%)
No data 1 (2%)
Outcome
Died 10 (19%)
Survived 42 (81%)
Normal 19/42 (45%)
Moderately abnormal 12/42 (29%)
Severely abnormal 8/42 (19%)
No follow-up data 3/42 (7%)
Follow-up 9 months 13/42 (36.1%)
Table 2. Clinical and Prothrombotic Risk Factors in 52
Neonates With SVT
Risk Factors No. (%)
Maternal
Pre-eclampsia/HELLP syndrome 7 (13.4%)
Pregnancy induced- or pre-existing diabetes 3 (5.8%)
Maternal shock 1 (1.9%)
Maternal surgery 1 (1.9%)
History of clotting disease* 1 (1.9%)
Perinatal
Complicated delivery† 31 (60%)
Perinatal asphyxia 3 (5.8%)
Fetomaternal transfusion 1 (1.9%)
Neonatal
Sepsis or meningitis 8 (15.4%)
Dehydration 1 (1.9%)
Congenital heart defect 1 (1.9%)
ECMO 1 (1.9%)
Prothrombotic Risk Factors
Patients Tested, Result,
Median Value, Range
Antithrombin level 29/52, normal, median: 69%, range
39–145%
Protein C level 32/52, normal, median: 37%, range
10–86%
Protein S level 32/52, normal, median: 56%, range
10–100%
FV G1691A mutation 41/52, present in 2/41 (4.9%)
FII G20210A mutation 18/52, present in 2/18 (11%)
MTHFR C677T- and A1298C
homo- or heterozygous mutations
23/52, present in 13/23 (56.5%)
Homocysteine level 23/52, normal, median: 6.0 mg/L;
range 4–16.3 mg/L
Lipoprotein a 16/52, normal, median: 21.5 mg/L;
range 0–322 mg/L
*Deep venous thrombosis and pulmonary emboli.
†Ventouse, forceps delivery, or emergency cesarean section.
HELLP indicates hemolytic anemia, elevated liver enzymes, low platelet
count; ECMO, extracorporeal membrane oxygenation procedure; MTHFR,
methylene tetrahydrofolate reductase.
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erlands Perinatal Registry. In this register, birth data from the Dutch
Midwifes Registry (LVR1, 94% complete) and data from the Dutch
Gynecological Society (LVR2, 99% complete) are recorded, culmi-
nating in a total coverage of 94% of deliveries in The Netherlands.
Due to logistical reasons, only 2000 to 2007 data could be used for
incidence calculation. To validate the number of patients with SVT
identified in our cohort, we searched the National Newborn Classi-
fication of Diseases Code Registry (LNR). However, no code for
cerebral venous thrombosis existed at the time. Therefore, we
depended on databases of participating centers (nominator) and the
birth registry (numerator).
Clinical Data Collection
Extensive chart reviews were performed to collect clinical data
(Table 1).
Known or suspected maternal, perinatal, neonatal, and prothrom-
botic risk factors for SVT were evaluated. Each neonatal intensive
care unit used a local protocol for investigating prothrombotic
disorders. Although variability existed between local protocols,
prothrombotic screening investigations were based on known guide-
lines for prothrombotic screening in pediatric patients17,18 All neo-
nates underwent routine hematologic and biochemical evaluation.
Neuroimaging and Neurophysiology
Cranial ultrasound using a broadband 5- to 8.5-MHz transducer
(depending on the participating center) was part of every diagnostic
workup. Color Doppler examination was performed in case of
clinical or ultrasound suspicion of SVT. MRI (1.5- or 3.0-Tesla
systems) was performed for clinical reasons and MRV (time-of-
flight imaging) was added when indicated. SVT was confirmed with
MRV in all cases. Neonatal MRI included T1-weighted sagittal,
T2-weighted axial, T1-weighted or inversion recovery axial images,
apparent diffusion coefficient, and diffusion-weighted images.
Clearly visible complete or partial absence of flow in 1 cerebral
venous sinus on MRV or color Doppler ultrasound was defined as
a sign of venous thrombosis. Patients with suspected SVT were
excluded. All imaging results were reviewed by the authors most
experienced in evaluating neonatal sinus thrombosis (F.G.,
L.S.d.V., P.G.).
Neurophysiology studies included amplitude integrated electroen-
cephalography (aEEG) and conventional EEG registrations (aEEG,
Olympic6000 and BRM2; Natus Medical Systems). These were
reviewed for each patient for presence of seizures and background
pattern. Tracings were scored as follows: seizure activity: none,
single seizure, recurrent seizures, or status epilepticus; background
activity: normal, abnormal, or severely abnormal according to age.
Neurodevelopmental Outcome
All patients received neurodevelopmental follow-up examinations
by a developmental pediatrician skilled and trained in long-term
neonatal follow-up or a pediatric neurologist. Outcome was deter-
mined by presence or absence of cognitive and/or motor deficits or
seizures at the latest visit. Outcome was defined as normal in
survivors with a normal clinical neurological examination, absence
of hearing or visual impairment and normal age-corrected Bayley
States of Infant Development (BSID-II),17 or Griffiths developmen-
tal assessment scales18 results. Outcome was recorded as moderately
abnormal in infants with moderate cerebral palsy, delayed motor
development, delay in speech development, and/or BSID-II-NL/
Griffiths score1 SD of the mean. Outcome was defined as severely
abnormal in the presence of severe cerebral palsy, inability to sit at
2 years of age, nonambulatory status, sensorineural hearing loss
requiring aids, bilateral blindness, and/or a BSID-II-NL/Griffiths
score 2 SD of the mean.
Statistical Analysis
Statistical analysis was performed with SPSS Version 16.0 software
package (SPSS, Chicago, Ill). Data are presented as median and
range. Descriptive statistics were used to analyze patient demo-
graphic data. Comparison of platelet counts at presentation and time
of diagnosis was performed using the Wilcoxon rank test for
nonparametric data, because results were not distributed normally.
The 95% CIs for incidence data were calculated with the Confidence
Interval Analysis software, Version 2.2.0 (University of Southamp-
ton School of Medicine).
Results
Patient Characteristics and Risk Factors
Fifty-two neonates were included in the study (Figure 2).
Table 1 describes patient characteristics. Forty-seven patients
Figure 2. Population flow sheet. FU indicates
long-term follow-up; Dev. pediatricians, devel-
opmental pediatricians; Ped. neurologists, pedi-
atric neurologists.
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were born in Level II hospitals, subsequently discharged,
readmitted with severe symptoms after a disease-free interval,
and transferred to 1 of the Level III centers. Five were born
in a tertiary center because of perinatal asphyxia (n3,
according to American Congress of Obstetricians and Gyne-
cologists criteria)17 known cardiac malformation (1), or
antenatally diagnosed hydrocephalus. (1) The vast majority
(75%) of our patients were male. Prevalence of known or
suspected maternal, perinatal, neonatal, and prothrombotic
risk factors for neonatal SVT in our cohort is shown in Table
2. Only term neonates were included in incidence calculation.
We identified preterm newborns with neonatal SVT; how-
ever, their number was small and we assumed preterm and
term SVT were not fully comparable due to gestational
age-related differences in brain and clotting system develop-
ment. Therefore, the incidence in this group is unknown. The
yearly incidence rate in term newborns varied from 1.4 (95%
CI, 0.04 to 8.01) per 100 000 in 2000 to 12 (95% CI, 5.20 to
23.73) per 100 000 in 2007 (supplemental Table I, available
online at http://stroke.ahajournals.org).
Presenting Symptoms and Clinical Course
The clinical presentation varied, as shown in Table 1, and was
independent of the cerebral sinus affected. Presenting symp-
toms consisted most frequently of seizures (n29 [55.8%])
and developed after a median time interval of 1.5 days
postnatally (range, 0 to 28 days).
Of the 42 neonates who experienced seizures at presenta-
tion (n29) or during clinical course (n13), 38 had cerebral
parenchymal lesions. In these patients, seizures were difficult
to control; on average, 2 antiepileptic drugs were needed
(range, 0 to 4). Only 5 of 43 neonates with parenchymal
lesions did not have clinical seizures. The extent of paren-
chymal injury could not be correlated with seizure activity.
Eighteen patients (35%) needed ventilatory support because
of respiratory insufficiency due to seizures or their treatment.
Laboratory Results
Biochemical evaluation was nonconspicuous in all cases.
There were no laboratory signs of dehydration. Median
hemoglobin count at time of presentation was 10.2 mmol/L
(range, 5.7 to 13.9 mmol/L). No statistically significant
difference (P0.384) was found in median platelet count at
presentation (197109/L; range, 55 to 573109/L) and at the
time of diagnosis (183109/L; range, 28 to 821109/L).
Prothrombotic screening results are summarized in Table
2. In all patients with proven methylene tetrahydrofolate
reductase mutation (n13), homocysteine plasma levels were
within normal range. Plasma levels of protein C, S, and
antithrombin were in the age-specific reference ranges in the
neonates tested.
Anticoagulation Therapy
Twenty-two neonates were treated with low-molecular-
weight heparin (LMWH) (n20) or unfractionated heparin
(n2), including neonates with thalamic hemorrhage (n10),
7 of which have been described in a previous report.19
Bleeding complications during treatment were not encoun-
tered. Heparin was started immediately after diagnosis and
LMWH was generally continued for 3 months.
Neuroimaging
Diagnosis of SVT was confirmed in all neonates by combined
MRI/MRV performed with differential diagnosis of SVT,
ischemic arterial stroke, or possible congenital cerebral mal-
formation. In 19 of 52 cases (37%) diagnosis was made by
screening color Doppler investigation. In 33 of 52 infants
(63%), SVT was solely diagnosed on MRI/MRV and not
recognized on initial ultrasound (Figure 1). Median time to
diagnosis (ultrasound or MRI/MRV) after admission was 4.0
days (range, 0 to 26 days).
Associated lesions (n43) like thalamic hemorrhage, in-
traventricular hemorrhage, or parenchymal hemorrhagic in-
farction were seen in 25 (48%), 29 (56%), and 41 (79%)
neonates, respectively. Table 3 provides an overview of
affected sinuses and associated cerebral lesions. Straight
sinus thrombosis or complex multiple-sinus thrombosis was
most frequently associated with severe hemorrhagic infarc-
tion of basal ganglia and/or thalamus. In patients with
multisinus thrombosis without associated cerebral lesions (3
of 26), the straight sinus was not involved. Multisinus
thrombosis was present in 9 of 10 newborns who died.
Table 3. Sinus Involved and Associated Cerebral Lesions in
52 Neonates With SVT
Sinus Involved No. (%) Associated Lesions*
Multiple sinuses 26 (50%) Thalamic hemorrhage (12)
Diffuse cytotoxic edema (4)
IVH (6)
Basal ganglia infarction (5)
No lesions (3)
Hydrocephalus (2)
Small single parenchymal infarction
(2: frontal 1, occipital 1)
Superior sagittal sinus 13 (23.1%) Parasagittal infarction (6)
Thalamic hemorrhage (4)
Basal ganglia infarction (3)
No lesions (2)
Straight sinus 8 (15.4%) Bilateral frontal infarction (3)
IVH (3)
Thalamic hemorrhage (2)
Diffuse cytotoxic edema (2)
Basal ganglia infarction (1)
Transverse sinus 3 (5.8%) No lesions (2)
Cerebellar hemorrhagic infarction (1)
Other 2 (3.8%)
Thalamostriatal
vein
Unilateral periventricular infarct
Internal cerebral
vein
Unilateral infarct head caudate
nucleus
*In some neonates, multiple associated lesions were present.
IVH indicates intraventricular hematoma.
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aEEG Monitoring
All patients were frequently monitored by full lead EEG, and
39 of 52 received continuous amplitude integrated EEG
monitoring, the results of which are displayed in Table 4.
Long-Term Outcome
Follow-up protocols differed per center. Table 1 shows
follow-up data. Neurodevelopment was uncomplicated in
45%, although 36% of our patients were still 9 months of
age when last seen. A severely abnormal outcome was
documented in 8 of 42 survivors (19%), 7 of whom had
multisinus thrombosis.
Visual deficits, like strabismus or uncoordinated eye move-
ments, occurred in 5 patients. Four developed posthemor-
rhagic hydrocephalus requiring ventricular peritoneal shunt-
ing. Postneonatal epilepsy was noted in 9 infants, of whom 7
needed long-term antiepileptic treatment. Mortality was high
(10 of 52 [19%]).
Discussion
This study confirms neonatal SVT is rare and usually presents
with seizures. Although differential diagnosis of neonatal
seizures is extensive, a history of complicated delivery,
perinatal asphyxia, or infection followed by a symptom-free
period should raise suspicion of SVT. This observation is in
accordance with previous reports.3,4,8,15,20
Neonatal and perinatal complications were present in over
three fourths of our neonates and may prove to be more
important than maternal risk factors. The high occurrence of
complicated or assisted deliveries was remarkable. A plausi-
ble etiology for the association of traumatic birth and SVT
could be severe changes in cerebral sinus venous flow during
peripartum skull molding,21,22 predisposing the neonate to
SVT by disruption of venous endothelium and activation of
the coagulation cascade, resulting in thrombus formation.
In agreement with other studies, a male predominance was
found.14 This observation is as yet unexplained. In a recent
publication, gender differences in pediatric thromboembolic
arterial ischemic stroke and venous thromboembolism were
associated with elevated testosterone levels in both male and
female affected patients.23,25 Gender-related differences in
testosterone levels may also play a role in neonatal SVT.24
The observed incidence of neonatal SVT is higher than
previously reported and could be due to increased awareness
and improved perinatal care resulting in increased survival of
neonates at risk. Thanks to extensive obstetric databases in
The Netherlands, our estimate seems reliable. Because no
active screening for SVT was performed, less severely
affected neonates may have remained undiagnosed. Prospec-
tive studies are desired and may disclose an even higher
incidence.
Neonatal brain lesions due to SVT found on MRI corre-
sponded with known drainage territories of dural venous
sinuses11 and were comparable to other reports,11,26,27 as was
the incidence of thalamic hemorrhage and intraventricular
hemorrhage.1,4,28 Deep white matter and basal ganglia are
drained by the internal cerebral and basal veins of Rosenthal,
which join to form the great vein of Galen, eventually
draining into the straight sinus. Either direct obstruction of
thalamic venous drainage or the internal cerebral vein leads to
hemorrhagic thalamic infarction.27 In our series, multiple-
sinus and straight sinus thrombosis invariably produced
severe lesions in the thalamus and basal ganglia. Intraven-
tricular hemorrhage during SVT is thought to result from
germinal matrix or choroid plexus hemorrhage caused by
obstructed venous flow at the vulnerable junction of 3 veins
(venous angle): the thalamostriatal vein, septal vein, and
choroidal vein.11,29
The value of prothrombotic screening still needs to be
determined. Because the content of screening protocols var-
ied among neonatal intensive care units and not all patients
were tested, no conclusions can be drawn regarding the
significance of prothrombotic risk factors in the development
of neonatal SVT. Protein S, C, and antithrombin examina-
tions were usually not repeated after the neonatal period and
none of the parents were tested. Therefore, congenital defi-
ciencies could not be ruled out. FV G1691A mutation was
present in 4.9%. FII G20210A mutation prevalence was 11%
in our tested patients, which is higher than in the white
population. The increased prevalence of FII G20210A muta-
tion found might be due to selection bias, because only 18 of
52 neonates were tested. Previous studies demonstrated
presence of FII G20210A mutation predicts recurrent throm-
bosis in children with SVT and/or deep venous thrombo-
sis.30,31 Because homocysteine levels were not elevated in any
of the patients with methylene tetrahydrofolate reductase
mutations, their relevance seems negligible.
Discussion remains regarding optimal treatment for neo-
natal SVT. Kenet and colleagues suggest anticoagulation
should be given on a patient-to-patient basis in children with
newly identified SVT and high risk of recurrence.32 In our
study, choice for treatment highly depended on clinician
Table 4. Seizures During the Clinical Course and
Neurophysiology Results at Presentation in 52 Neonates With
SVT (EEG Combined With aEEG Results)
No. (%)
Clinical seizures
At presentation 29 (56%)
At presentationduring clinical course 42 (80.8%)
No. of AEDs needed (median, range) 1 (0–4)
Neurophysiology results/seizures
Single seizure 5 (9.6%)
Recurrent seizures 18 (34%)
Status epilepticus 7 (13.5%)
No seizures 14 (26.9%)
No data 8 (15%)
Neurophysiology results/background
Background activity
Normal for age 24 (46.2%)
Moderately depressed 10 (19.2%)
Severely depressed 7 (13.5%)
No data 11 (21%)
AEDs indicates antiepileptic drugs.
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preferences in the absence of guidelines. Severely affected
neonates with deep or multisinus thrombosis, complicated by
intracerebral hemorrhage, usually received none for fear of
hemorrhagic complications (Figure 2). Therefore, treatment
effect on outcome cannot be reliably evaluated in our cohort.
In a recent extensive international prospective study, multi-
variate analysis of factors influencing treatment decisions in
neonatal SVT failed to demonstrate presence of intracranial
hemorrhage as a major reason to withhold treatment.30 Clot
propagation has been reported in 25% of affected infants.
Although not based on clinical trials, unfractionated heparin
or low-molecular-weight heparin administration is therefore
advised in patients with SVT for a minimum period of 6
weeks and no longer than 3 months.31,33
There are substantial differences in reported neonatal
SVT neurodevelopmental outcome data.1,4,5,28,34 In our
cohort, outcome in survivors was normal in 45%, neuro-
logical deficits were seen in 47%, and persistent epilepsy
in 16%. These results are comparable with those of
deVeber et al.5 In the only other study focusing solely on
neonatal SVT, more adverse sequelae occurred.35 Because
of our relatively short follow-up period (36% of patients
being younger than 9 months), no definite conclusions
regarding final outcome can be drawn. Lack of a standard-
ized neurodevelopmental follow-up protocol may have
influenced outcome data. Mortality in our cohort (19%) is
higher than previously reported1,4 and may reflect identi-
fication of the most severely affected neonates with
extensive parenchymal damage.
In conclusion, neonatal SVT is a multifactorial disease
with a significant risk of serious adverse neurological se-
quelae. It is increasingly diagnosed and incidence proved
higher in our population than previously reported. Compli-
cated delivery seemed the major risk factor and most infants
presented with seizures. Although treatment with low-
molecular-weight heparin in neonatal SVT appears safe,
international collaboration should be sought for in documen-
tation and evaluation of these patients to develop evidence-
based treatment guidelines.
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